NCT06589804 2026-04-17Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentNational Cancer Institute (NCI)Phase 3 Recruiting158 enrolled
NCT03091192 2026-04-14Savolitinib vs. Sunitinib in MET-driven PRCC.AstraZenecaPhase 3 Active not recruiting60 enrolled 15 charts
NCT07222566 2026-04-08Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerPfizerPhase 3 Recruiting1,410 enrolled
NCT07441681 2026-04-03Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive CisplatinNRG OncologyPhase 3 Not yet recruiting454 enrolled